Epcoritamab-bysp in Combination with Rituximab and Lenalidomide Approved as Treatment Option for Relapsed or Refractory Follicular Lymphoma in the U.S.
On November 18, 2025, the FDA approved epcoritamab-bysp (EPKINLY®) in combination with rituximab and lenalidomide for adults with relapsed or refractory follicular lymphoma after at least one prior therapy. This approval applies to patients in the United States..
Choosing Your Next Treatment: What FL (follicular lymphoma) Patients Should Know
Watch this webinar from November 2025 where the panel discusses and shares insights on what matters most to doctors and FL patients when navigating their next treatment options.